| Primary |
| Acute Myeloid Leukaemia |
56.3% |
| Acute Promyelocytic Leukaemia |
7.8% |
| Prophylaxis |
7.1% |
| Infection |
3.6% |
| Pyrexia |
3.1% |
| Chemotherapy |
2.6% |
| Non-hodgkin's Lymphoma |
2.2% |
| Graft Versus Host Disease |
2.1% |
| Acute Lymphocytic Leukaemia |
1.8% |
| Pain |
1.7% |
| T-cell Lymphoma |
1.7% |
| Acute Monocytic Leukaemia |
1.4% |
| Multiple Myeloma |
1.4% |
| Stem Cell Transplant |
1.3% |
| Sepsis |
1.1% |
| Antiemetic Supportive Care |
1.0% |
| Bronchopulmonary Aspergillosis |
1.0% |
| Myelodysplastic Syndrome |
1.0% |
| Nausea |
1.0% |
| Antibiotic Therapy |
0.8% |
|
| Febrile Neutropenia |
18.0% |
| Sepsis |
7.9% |
| Thrombocytopenia |
6.7% |
| White Blood Cell Count Decreased |
6.7% |
| Pneumonia |
5.6% |
| Clostridial Infection |
4.5% |
| Neutropenia |
4.5% |
| Overdose |
4.5% |
| Rash |
4.5% |
| Bronchitis |
3.4% |
| Cardiac Arrest |
3.4% |
| Hyperbilirubinaemia |
3.4% |
| Intestinal Obstruction |
3.4% |
| Mucosal Inflammation |
3.4% |
| Renal Failure |
3.4% |
| Respiratory Failure |
3.4% |
| Septic Shock |
3.4% |
| Staphylococcal Infection |
3.4% |
| Swelling |
3.4% |
| Vomiting |
3.4% |
|
| Secondary |
| Acute Myeloid Leukaemia |
36.8% |
| Acute Promyelocytic Leukaemia |
16.8% |
| Product Used For Unknown Indication |
8.2% |
| Acute Lymphocytic Leukaemia |
6.2% |
| Prophylaxis |
5.9% |
| Myelodysplastic Syndrome |
4.5% |
| Acute Myeloid Leukaemia Recurrent |
2.7% |
| Drug Use For Unknown Indication |
2.6% |
| Haematological Malignancy |
2.3% |
| Acute Leukaemia |
2.2% |
| Non-hodgkin's Lymphoma |
1.8% |
| Acute Monocytic Leukaemia |
1.5% |
| Bone Marrow Conditioning Regimen |
1.3% |
| Pyrexia |
1.3% |
| Multiple Myeloma |
1.1% |
| Diffuse Large B-cell Lymphoma |
1.0% |
| Febrile Neutropenia |
0.9% |
| Antifungal Prophylaxis |
0.9% |
| Graft Versus Host Disease |
0.9% |
| Chemotherapy |
0.9% |
|
| Sepsis |
13.0% |
| Acute Myeloid Leukaemia |
10.6% |
| Myelodysplastic Syndrome |
9.9% |
| Pneumonia |
8.3% |
| Septic Shock |
6.5% |
| Febrile Neutropenia |
5.6% |
| Thrombocytopenia |
5.4% |
| Haemorrhage Intracranial |
4.9% |
| Multi-organ Failure |
4.7% |
| Chronic Myelomonocytic Leukaemia |
3.2% |
| Respiratory Failure |
3.2% |
| Renal Failure |
3.1% |
| Vomiting |
3.1% |
| Neutropenia |
2.9% |
| Pyrexia |
2.9% |
| Pancytopenia |
2.7% |
| Pulmonary Haemorrhage |
2.7% |
| White Blood Cell Count Decreased |
2.7% |
| Cytogenetic Abnormality |
2.3% |
| Infection |
2.3% |
|
| Concomitant |
| Acute Myeloid Leukaemia |
18.8% |
| Acute Promyelocytic Leukaemia |
12.6% |
| Prophylaxis |
8.1% |
| Acute Lymphocytic Leukaemia |
7.9% |
| Diffuse Large B-cell Lymphoma |
7.6% |
| Anaemia Haemolytic Autoimmune |
7.1% |
| Stem Cell Transplant |
4.6% |
| Drug Use For Unknown Indication |
4.1% |
| Plasmacytoma |
3.8% |
| Product Used For Unknown Indication |
3.8% |
| Prophylaxis Against Graft Versus Host Disease |
3.8% |
| Chemotherapy |
3.0% |
| Multiple Myeloma |
2.5% |
| Bone Marrow Conditioning Regimen |
2.1% |
| Pneumonia |
1.8% |
| Sepsis |
1.8% |
| Neoplasm Malignant |
1.7% |
| Abdominal Pain |
1.6% |
| Antifungal Prophylaxis |
1.6% |
| Infection Prophylaxis |
1.6% |
|
| Vomiting |
10.0% |
| White Blood Cell Count Decreased |
10.0% |
| Retinoic Acid Syndrome |
7.1% |
| Sepsis |
7.1% |
| Acute Myeloid Leukaemia |
6.5% |
| Septic Shock |
5.9% |
| Progressive Multifocal Leukoencephalopathy |
4.7% |
| Stomatitis |
4.7% |
| Thrombocytopenia |
4.7% |
| X-ray Abnormal |
4.7% |
| Myelodysplastic Syndrome |
4.1% |
| Pyrexia |
4.1% |
| Renal Impairment |
4.1% |
| Thrombotic Microangiopathy |
4.1% |
| Disseminated Intravascular Coagulation |
3.5% |
| Neuropathy Peripheral |
2.9% |
| Platelet Count Decreased |
2.9% |
| Renal Failure Acute |
2.9% |
| Toxic Encephalopathy |
2.9% |
| Wrong Drug Administered |
2.9% |
|
